Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL227 Target Snapshot

Type-1 angiotensin II receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
3,352Compounds
320Assays
19Approved Drugs
1,804.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Type-1 angiotensin II receptor shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block. 14 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P30556. Start with hypertension, then reuse UniProt P30556 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with hypertension, then reuse UniProt P30556 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 14 linked drugs
Open source guide
Disease program
hypertension

Type-1 angiotensin II receptor shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block. 14 linked drugs remain visible in the same block.

Start review with hypertension because it currently carries approved-linked support. Linked drugs include AZILSARTAN, AZILSARTAN KAMEDOXOMIL, CANDESARTAN, CANDESARTAN CILEXETIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 14 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Type-1 angiotensin II receptor as ChEMBL target CHEMBL227, mapped to UniProt P30556. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Type-1 angiotensin II receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL227
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P30556
Type-1 angiotensin II receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Type-1 angiotensin II receptor is the right protein anchor across sources, using UniProt P30556 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why hypertension is currently framed as approved-linked support. It currently carries 14 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameType-1 angiotensin II receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP30556
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelType-1 angiotensin II receptor
UniProt AccessionP30556
Component TypeProtein
Sequence Length359 aa

Type-1 angiotensin II receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Type-1 angiotensin II receptor, mapped to UniProt P30556. Sequence length is 359 aa.

Mapped IDP30556
Review nameType-1 angiotensin II receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Type-1 angiotensin II receptor shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
hypertension
14 linked drugs · 14 direct · 14 efficacy
Linked drugAZILSARTAN
Linked drugAZILSARTAN KAMEDOXOMIL
Linked drugCANDESARTAN
Linked drugCANDESARTAN CILEXETIL
Approved-linked Approved
cardiovascular disease
8 linked drugs · 8 direct · 8 efficacy
Linked drugCANDESARTAN
Linked drugCANDESARTAN CILEXETIL
Linked drugFIMASARTAN
Linked drugIRBESARTAN
Approved-linked Approved
stroke
7 linked drugs · 7 direct · 7 efficacy
Linked drugAZILSARTAN KAMEDOXOMIL
Linked drugCANDESARTAN CILEXETIL
Linked drugLOSARTAN POTASSIUM
Linked drugOLMESARTAN
Approved-linked Approved
type 2 diabetes mellitus
6 linked drugs · 6 direct · 6 efficacy
Linked drugAZILSARTAN
Linked drugCANDESARTAN
Linked drugCANDESARTAN CILEXETIL
Linked drugIRBESARTAN
Approved-linked Approved
diabetes mellitus
5 linked drugs · 5 direct · 5 efficacy
Linked drugAZILSARTAN
Linked drugCANDESARTAN CILEXETIL
Linked drugOLMESARTAN MEDOXOMIL
Linked drugTELMISARTAN
Approved-linked Approved
heart failure
5 linked drugs · 5 direct · 5 efficacy
Linked drugCANDESARTAN
Linked drugCANDESARTAN CILEXETIL
Linked drugOLMESARTAN MEDOXOMIL
Linked drugTRV-120027
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with hypertension because it currently carries approved-linked support. Linked drugs include AZILSARTAN, AZILSARTAN KAMEDOXOMIL, CANDESARTAN, CANDESARTAN CILEXETIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasehypertension
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

19
Approved
4
Phase III
7
Phase II
1
Phase 0.5
Assay Mix

Activity Type Distribution

IC501,232.0
KI254.0
EC50293.0
KD25.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL275875 10.9 Kd 0.01259 Preclinical
CHEMBL47177 10.9 Kd 0.01259 Preclinical
CHEMBL346728 10.3 IC50 0.05 Preclinical
CHEMBL305017 10.0 IC50 0.1 Preclinical
CHEMBL70370 10.0 IC50 0.1 Preclinical
CHEMBL70161 10.0 IC50 0.1 Preclinical
CHEMBL70935 10.0 IC50 0.1 Preclinical
CHEMBL70843 10.0 IC50 0.1 Preclinical
CHEMBL70789 10.0 IC50 0.1 Preclinical
CHEMBL24322 10.0 IC50 0.1 Preclinical
Distribution

pChEMBL Value Distribution

120
5.0
69
5.5
84
6.0
77
6.5
110
7.0
178
7.5
154
8.0
180
8.5
127
9.0
34
9.5
pChEMBL
Approved Drugs

Approved Drugs

SPARSENTAN
CHEMBL539423
Approved 2023
Properties Compare Identifier
ANGIOTENSIN II
CHEMBL408403
Approved 2017
Properties Compare Identifier
TELMISARTAN
CHEMBL1017
Approved 1998
Properties Compare Identifier
IRBESARTAN
CHEMBL1513
Approved 1997
Properties Compare Identifier
EPROSARTAN
CHEMBL813
Approved 1997
Properties Compare Identifier
VALSARTAN
CHEMBL1069
Approved 1996
Properties Compare Identifier
LOSARTAN
CHEMBL191
Approved 1995
Properties Compare Identifier
LOSARTAN POTASSIUM
CHEMBL995
Approved 1995
Properties Compare Identifier
SARALASIN
CHEMBL938
Approved 1982
Properties Compare Identifier
Assay Landscape

Assay Landscape

320
Total Assays
852
Tested Compounds
3
Assay Types
Binding — 267 assays, 852 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 171 453 8.1
cell-based format 80 281 7.4
assay format 6 21 7.3
cell membrane format 4 62 8.3
tissue-based format 4 12 8.3
organism-based format 2 23 8.2
Functional — 52 assays, 352 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 28 39 7.3
assay format 22 311 5.3
single protein format 2 2 8.7
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine